Production and chemical processing of low molecular weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 5-16

  Linhardt, Robert J ^a   Sibel Gunay, N U R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Analysis; Low molecular weight heparin; Process; Production; Structure

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DEAMINATION; DEPOLYMERIZATION; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG QUALITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR STRUCTURE;

EID: 0032745131     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Linhardt RJ, Toida T. Heparin oligosaccharides: New analoguesdevelopment and applications. In: Witczak ZJ, Nieforth KA, eds. Carbohydrates in Drug Design. New York: Marcel Dekker; 1997:277-341
2. Linhardt RJ. Heparin: An important drug enters its seventh decade. Chem Indust 1991;2:45-50
3. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev 1994;46: 89-110
4. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:l-7
5. Donayre CE. Current use of low molecular weight heparins. Semin Vascul Surg 1996;9:362-371
6. Hunt D. Low molecular weight heparins in clinical practice. Southern Medical J 1998;91:2-10
7. Farced J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low molecular weight heparins: Pharmacologie profile and product differentiation. Am J Cardiol 1998;82:3L-10L
8. Rosenberg RD. Biochemistry and pharmacology of low molecular weight heparin. Semin Hematol 1997:34:2-8
9. Rosenberg RD, Damus PS. The purification and mechanism of action of human antilhrombin-heparin cofactor. J Biol Chem 1973:248:6490-6505
10. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to heparin than anticoagulation. Thromb Res 1994;75:1-32
11. Fussi F. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties and products so obtained. US patent #4281108, 1981
12. Lindahl U, Backstrom GE, Thunberg J, et. al. Heparin fragments having selective anticoagulant activity. US patent #4303651, 1981
13. Bamett WE. Anticoagulant substance. US patent #4351938,1982
14. Loremeau J-C, Choay J, Petitou M. Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them. US patent #4401662, 1983
15. Langer RS, Linhardt RJ, Cooney CL, Fitzgerald G, Grant A. Heparinase derived anticoagulants. US Patent #4396762,1983
16. Lindahl U, Backstrom G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombinbinding sequence of heparin. Proc Natl Acad Sei (USA) 1980; 77:6551-6555
17. Atha DH, Lormeau J-C, Petitou M, Rosenberg RD, Choay J. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 1985:24:6723-6729
18. Linhardt RJ, Rice KG, Kim YS, et al. Mapping and quantification of the major oligosaccharide components of heparin. Biochem J 1988:254:781-787
19. Loganathan D, Wang HM, Malus LM, Linhardt RJ. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 1990:29:4362-1368
20. Pervin A, Gallo C, Jandik KA, Han X-J, Linhardt RJ. Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology 1995:5:83-95
21. Gatti G, Casu B, Hamer GK, Perlin AS. Studies on the conformation of heparin by 1H and 13CNMR spectroscopy. Macromol 1979:12:1001-1007
22. Mulloy B, Forster MJ, Jones C, Davies DB. NMR and molecularmodelling studies of the solution conformation of heparin. Biochem J 1993:293:849-858
23. Mikhailov D, Linhardt RJ, Mayo KH. NMR solution conformation of heparin-derived hexasaccharide. Biochem J 1997;328:51-61
24. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science 1996:271:1116-1120
25. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interaction: Definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 1998;20:156-167
26. Conrad HE. Heparin-Binding Proteins. San Diego, CA: Academic Press;1998:l-527
27. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Pharmacol Rev 1991:71:481-539
28. Ahsan A, Jeske W, Hoppensteadt D, Lormeau JC, Wolf H, Farced J. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sei 1995:84:724-727
29. Mulloy B, Gee C, Wheeler SF, et al. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Hemost 1997:77:668-674
30. Griffin CC, Linhardt RJ, VanGorp CL, et al. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosapeptidoglycan heparin. CarbohydrRes 1995;276:183-197
31. Yamada S, Sugahara K. Structure of oligosaccharides isolated from heparan sulfate/heparin and substrate specificities of the degrading enzymes of bacterial origin. Trends Glycosci Glycotechnol 1998:10:95-123
32. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: A piece of information. FASEB J 1996:10:1270-1279
33. Gallagher JT, Walker A. Molecular distinctions between heparan sulphate and heparin. Biochem J 1985;230:665-674
34. Marcum JA, Rosenberg RD. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin Tliromb Hemost 1987;13:464-474
35. Neville GA, Mori F, Holme KR, Perlin AS. Monitoring the purity of pharmaceutical heparin preparations by high-field IH-nuclear magnetic resonance spectroscopy. J Pharm Sei 1989;78: 101-104
36. Edens RE, Fromm JR, Fromm S J, Linhardt RJ, Weiler JM. Twodimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III. Biochemistry 1995;34:2400-2407
37. Coyne E. Heparin - past, present and future. In: Lundblad RL, Brown WV, Mann KG, Roberts HR, eds. Chemistry and Biology of Heparin. Amsterdam, Holland: Elsevier North Holland; 1981:9-17
38. Vidic H-J. Process for the preparation of heparin. US patent #4283530, 1981
39. Okuyama T. Yoshida K, Sakuraik M, et al. Method of separating and recovering mucopolysaccharides from connective tissue of animals. US patent #3862003,1975
40. Williams RE. Process for the recovery of heparin. US patent #3337409,1967
41. European Pharmacopeia Commission. Pharmeuropa 1991;3: 161-165
42. Coyne E. From heparin to heparin fractions and derivatives. Semin Thromb Hemost 1985;11:10-12
43. Branelllec JF, Espego J, Picart P. Purified heparin fractions, method for obtaining them and pharmaceutical compositions containing them. US patent #5599801, 1997
44. Jandik K, Kruep D, Cartier M, Linhardt RJ. Accelerated stability studies of heparin. J Pharm Sei 1996:85:45-51
45. Lohse DL, Linhardt RJ. Purification and characterization of heparin lyases from flavobacterium heparimim, J Biol Chem 1992:267:24347-24355
46. Linhardt RJ. Analysis of glycosaminoglycans with polysaccharide lyases. In: Varki A, ed. Current Protocols in Molecular Biology, Analysis of Glycoconjugates, Boston, MA: Wiley Interscience; 1994:V2, 17.13.17-17.13.32
47. Mardiguian JS. Heparin esters and process for their preparation. US patent #4440926, 1984
48. Fussi F. Process for obtaining low molecular weight heparins. European Patent GB2,002,406B, 1982
49. De Ambrosi L, Recchia W, Ferrari G. Process for the controlled preparation of low molecular weight glycosaminoglycans. US patent #4987222, 1991
50. Jeske W, Iqbal O, Gonnela S, et. al. Pharmacologie profile of a low molecular weight heparin depolymerized by -y-irradiation. Semin Thromb Hemost 1995;21:201-211
51. Linhardt RJ, Loganathan D, Al-Hakim et al. Oligosaccharide mapping of low molecular weight heparins: Structure and activity differences. J Med Chem 1990:33:1639-1645
52. Fussi F, Fedeli GF. Oligo-heteropolysaccharides a activité semblable a celle de l'héparine, procède pour leur préparation et compositions thérapeutiques correspondantes. French patent # FR 78 23499, 1978
53. Lormeau J-C, Petitou M, Choay J. Oligosaccharides having antiXa activity and pharmaceutical compositions containing them. US patent #RE 35770, 1998
54. Lormeau J-C, Petitou M, Choay J. Method for obtaining biologically active mucopolysaccharides of high purity by controlled depolymerization of heparin. US patent #5019649, 1991
55. Nielsen JI. Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin. US patent #5106734, 1992
56. Piani S, Tamagnone G, Alpino RR, Milani MR. Heparin derivatives and process for their preparation. US Patent #5010063, 1991
57. Lopez, LL. Depolymerization method of heparin. US patent #4981955, 1991
58. Uzan A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof. US patent #5849721, 1998
59. Toida T, Hileman RE, Smith AE, Vlahova PI, Linhardt RJ. Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites. J Biol Chem 1996:271:3204032047
60. Toida T, Yoshida H, Toyoda H, et al. Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem J 1997;322: 499-506
61. Linhardt RJ. Chemical and enzymatic methods for the depolymerization and modification of heparin. In: Ogura H, Hasegawa A, Suami T, eds. Carbohydrates-Synthetic Methods and Applications in Medicinal Chemistry. Tokyo: Kodansha/VCH Publishers; 1992:385-401
62. Van Dedem G, Nielsen JI. Determination of the molecular mass of low molecular mass (LMM) heparin. Pharmeuropa 1991;3: 202-225
63. Rice KG, Kim YS, Grant AC, Merchant ZM, Linhardt RJ. Highperformance liquid Chromatographie separation of heparin derived oligosaccharides. Anal Biochem 1985;150:325-331
64. Guo Y, Conrad H. The disaccharide composition of heparins and heparan sulfates. Anal Biochem 1989:176:96-104
65. Pervin A, Al-Hakim A, Linhardt RJ. Separation of glycosaminoglycan-derived oligosaccharides by capillary electrophoresis using reverse polarity. Anal Biochem 1994;221:182-188
66. Desai UR, Hoppensteadt D, Farced J, Linhardt RJ. Measurement of the antithrombin III binding sites in low molecular weight heparins using I3C NMR and capillary electrophoresis. Pharm Sei 1995:1:349-353
67. Desai UR, Wang HM, Ampofo SA, Linhardt RJ. Oligosaccharide composition of heparin and low molecular weight heparins by capillary electrophoresis. Anal Biochem 1993:213: 120-127
68. Edens RE, Al-Hakim A, Weiler JM, Rethwisch DG, Fareed J, Linhardt RJ. Gradient polyacrylamide gel electrophoresis for determination of the molecular weights of heparin preparations and low molecular weight heparin derivatives. J Pharm Sei 1992:81:823-827
69. Casu, B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985:43:51-134
70. Desai UR, Linhardt RJ. Molecular weight of heparin using 13C nuclear magnetic resonance spectroscopy. J Pharm Sei 1995; 84:212-215
71. Desai UR, Linhardt RJ. Molecular weight of low molecular weight heparins by I3C nuclear magnetic resonance spectroscopy. Carbohydr Res 1994;255:193-212
72. Mallis LM, Wang HM, Loganathan D, Linhardt RJ. Sequence analysis of highly sulfated heparin-derived oligosaccharides using fast atom bombardment mass spectrometry. Anal Chem 1989:61:1453-1458
73. Lamb DJ, Wang HM, Mallis LM, Linhardt RJ. Negative ion fastatom bombardment tandem mass spectrometry to determine sulfate and linkage position in glycosaminoglycan-derived disaccharides. J Am Soc Mass Spectrom 1992:3:797-803
74. Toida.T, Linhardt,RJ. Structural analysis of heparan sulfate and heparan sulfate oligosaccharides. Trends Glycosci Glycotechnol 1998:10:125-136
75. Rhomberg AJ, Ernst S, Sasisekharan R, Biemann K. Mass spectrometric and capillary elctrophoretic investigation of the enzymatic degradation of heparin-Iike glycosaminoglycans. Proc NatlAcadSci(USA) 1998;95:4176-4181
76. Atha DH, Coxon B, Reipa V, Gaigalas AK. Physicochemical characterization of low molecular weight heparin. J Pharm Sei 1995;84:360-364
77. Stone AL. Far-ultraviolet circular dichroism and uronic acid components of anticoagulant deçà-, dodeca-, tetradeca-, and octadecasaccharides from heparin fractions. Arch Biochem Biophys 1985;236:342-353
78. Wade A, Weller PJ. eds. Handbook of Pharmaceutical Excipients. Washington, DC: American Pharmaceutical Association 1994; 1-651
79. Schonberger LB. New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Infect Disease Clinics North Am 1998;12:111-21
80. Farced J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22:77-91
81. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-322